Ken Garber

4.9k total citations
177 papers, 3.8k citations indexed

About

Ken Garber is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Ken Garber has authored 177 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Molecular Biology, 37 papers in Oncology and 27 papers in Immunology. Recurrent topics in Ken Garber's work include Science, Research, and Medicine (14 papers), CAR-T cell therapy research (13 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Ken Garber is often cited by papers focused on Science, Research, and Medicine (14 papers), CAR-T cell therapy research (13 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Ken Garber collaborates with scholars based in United States and Germany. Ken Garber's co-authors include Peng Jin, Chadwick M. Hales, Lin Li, Laura DeFrancesco, Robert Guderian, Esther Landhuis, Michael Eisenstein, Daniel Clery, Gretchen Vogel and Kelly Servick and has published in prestigious journals such as Nature, Science and Nature Medicine.

In The Last Decade

Ken Garber

177 papers receiving 3.7k citations

Peers

Ken Garber
Teck Yew Low Malaysia
Nancy Krett United States
Gareth I. Owen Chile
Amanda McCann Ireland
Xinyuan Liu China
Mark Merchant United States
Catherine Nguyen France
Stephan Geley Austria
Junnian Zheng China
Andrew Gilmore United Kingdom
Teck Yew Low Malaysia
Ken Garber
Citations per year, relative to Ken Garber Ken Garber (= 1×) peers Teck Yew Low

Countries citing papers authored by Ken Garber

Since Specialization
Citations

This map shows the geographic impact of Ken Garber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Garber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Garber more than expected).

Fields of papers citing papers by Ken Garber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Garber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Garber. The network helps show where Ken Garber may publish in the future.

Co-authorship network of co-authors of Ken Garber

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Garber. A scholar is included among the top collaborators of Ken Garber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Garber. Ken Garber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Garber, Ken. (2025). Probing the proteome. Nature Biotechnology. 43(8). 1216–1220. 2 indexed citations
2.
Garber, Ken. (2025). First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon. Nature Reviews Drug Discovery. 24(3). 155–157. 1 indexed citations
3.
Garber, Ken. (2022). The lysosomal degraders. Nature Biotechnology. 40(12). 1709–1713. 11 indexed citations
4.
Eisenstein, Michael, Ken Garber, Esther Landhuis, & Laura DeFrancesco. (2022). Nature Biotechnology’s academic spinouts 2021. Nature Biotechnology. 40(11). 1551–1562. 6 indexed citations
5.
Garber, Ken. (2020). Histone-writer cancer drugs enter center stage. Nature Biotechnology. 38(8). 909–912. 7 indexed citations
6.
Garber, Ken. (2020). γδ T cells bring unconventional cancer-targeting to the clinic — again. Nature Biotechnology. 38(4). 389–391. 20 indexed citations
7.
Eisenstein, Michael, et al.. (2020). Nature Biotechnology’s academic spinouts of 2019. Nature Biotechnology. 38(5). 546–554. 3 indexed citations
8.
Garber, Ken, Esther Landhuis, Cormac Sheridan, Melanie Senior, & Laura DeFrancesco. (2019). Nature Biotechnology’s academic spinouts of 2018. Nature Biotechnology. 37(6). 601–612. 6 indexed citations
9.
Garber, Ken, et al.. (2018). Nature Biotechnology's academic spinouts of 2017. Nature Biotechnology. 36(4). 297–306. 1 indexed citations
10.
Garber, Ken. (2018). Cytokine resurrection: engineered IL-2 ramps up immuno-oncology responses. Nature Biotechnology. 36(5). 378–379. 12 indexed citations
11.
Garber, Ken. (2016). Cancer anabolic metabolism inhibitors move into clinic. Nature Biotechnology. 34(8). 794–795. 34 indexed citations
12.
Garber, Ken. (2015). Predictive biomarkers for checkpoints, first tests approved. Nature Biotechnology. 33(12). 1217–1218. 11 indexed citations
13.
Li, Lin, Chadwick M. Hales, Ken Garber, & Peng Jin. (2014). Fat mass and obesity-associated (FTO) protein interacts with CaMKII and modulates the activity of CREB signaling pathway. Human Molecular Genetics. 23(12). 3299–3306. 45 indexed citations
14.
Garber, Ken. (2012). Mission Therapeutics. Nature Biotechnology. 30(3). 206–206. 1 indexed citations
15.
Garber, Ken. (2009). Trial Offers Early Test Case for Personalized Medicine. JNCI Journal of the National Cancer Institute. 101(3). 136–138. 10 indexed citations
16.
Garber, Ken. (2006). Realistic Rodents? Debate Grows Over New Mouse Models of Cancer. JNCI Journal of the National Cancer Institute. 98(17). 1176–1178. 27 indexed citations
17.
Garber, Ken. (2006). China Approves World's First Oncolytic Virus Therapy For Cancer Treatment. JNCI Journal of the National Cancer Institute. 98(5). 298–300. 366 indexed citations
18.
Garber, Ken. (2005). Missing the Target: Ubiquitin Ligase Drugs Stall. JNCI Journal of the National Cancer Institute. 97(3). 166–167. 21 indexed citations
19.
Garber, Ken. (2003). Big Plans for Small Molecules: NIH Launches Chemical Genomics Initiative. JNCI Journal of the National Cancer Institute. 95(23). 1740–1741. 4 indexed citations
20.
Garber, Ken. (2000). The next wave of the genomics business. Technology Review. 103(4). 46–56. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Teck Yew Low Breakdown of academic impact, for papers by Nancy Krett Breakdown of academic impact, for papers by Gareth I. Owen Breakdown of academic impact, for papers by Amanda McCann Breakdown of academic impact, for papers by Xinyuan Liu Breakdown of academic impact, for papers by Mark Merchant Breakdown of academic impact, for papers by Catherine Nguyen Breakdown of academic impact, for papers by Stephan Geley Breakdown of academic impact, for papers by Junnian Zheng Breakdown of academic impact, for papers by Andrew Gilmore
Rankless by CCL
2026